Methods Virally suppressed patients (HBV DNA <20 IU/mL at screening) on TDF were randomized (1:1) to switch to TAF or continue TDF for 48 weeks in a double-blind fashion. Viral suppression and changes in bone (BMD by DXA) and renal (creatinine clearance [eGFRCG]) parameters were assessed over 48 weeks.

Results Among the 400 Asian patients enrolled, 288 (72%) had at least 1 TDF RF. At Week 48, similar proportions with ≥1 RF had HBV-DNA <200IU/mL (TAF 97%; TDF 97%) and normal ALT by 2018 AASLD criteria (TAF 76%; TDF 73%). TAF subjects with ≥1 RF had increases in eGFRCG compared to decreases on TDF [median (Q1, Q3) change; TAF: +2.01 (-7.56, +15.79); p<0.0001)]. Among patients with ≥1 RF, improvements were seen in BMD for TAF vs. continued declines in TDF patients at both spine (p<0.0001) and hip (p<0.0001).

Conclusions Virally suppressed Asian patients with CHB and risk factors for TDF who switched to TAF showed improved bone and renal safety while efficacy was well-maintained.

IDDF2020-ABS-0059 SAFETY AND EFFICACY OF SOFOSBUVIR/VELPATASVIR (SOF/VEL) IN PEDIATRIC PATIENTS 6 TO < 18 YEARS OLD WITH CHRONIC HEPATITIS C (CHC) INFECTION

1Maureen Jonas, 2René Romero, 3Etienne Sokal, 4Philip Rosenthal, 5Gabriella Venutici, 6Chuan-Hao Lin, 7Jessica Wen, 8Michael Narkevicz, 9Sanjay Bansal, 10Jiang Shao, 11Sebi Heuel, 12Anuj Gaggar, 13Kathleen Schwarz. 1Boston Children’s Hospital, Boston, MA, USA; 2University of California San Francisco, San Francisco, USA; 3University of Bologna, Bologna, Italy; 4Children’s Hospital Los Angeles, Los Angeles, USA; 5University of Pennsylvania and The Children’s Hospital of Philadelphia, Pennsylvania, USA; 6University of Colorado School of Medicine and Children’s Healthcare of Atlanta, Atlanta, USA; 7Cliniques Universitaires Saint-Luc, UC Louvain, Brussels, Belgium; 8University of California San Francisco, San Francisco, USA; 9University of Bologna, Bologna, Italy; 10Children’s Hospital of Colorado, Aurora, USA; 11University of Pennsylvania and The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; 12University of Colorado School of Medicine and Children’s Hospital of Colorado, Aurora, USA; 13Kings College Hospital, London, UK; 14Gilead Sciences, Inc. Foster City, USA; 15Pediatric Gastroenterology, Hepatology and Liver Transplant, AdventHealth for Children, Orlando, USA; 16Baylor College of Medicine and Texas Children’s Hospital, Houston, USA; 17Cincinnati Children’s Hospital Medical Center, Cincinnati, USA; 18University of Washington School of Medicine and Seattle Children’s Hospital, Seattle, USA; 19Johns Hopkins University School of Medicine, Baltimore, USA

10.1136/gutjnl-2020-IDDF.142

Background DAA regimens have been approved for CHC treatment in 12 to <18 years, but for younger children, the standard of care is still pegylated-interferon plus ribavirin for ≤48 weeks. We evaluated the safety and efficacy of the pan-genotypic regimen of SOF/VEL in children 6 to <18 years. We evaluated the safety and efficacy of the pan-genotypic regimen of SOF/VEL in children 6 to <18 years.

Methods Patients 6 to <18 years with CHC of any genotype (GT) were enrolled in this open-label, ongoing study. Patients 6 to <12 years received SOF/VEL 200 mg/50 mg and 12 to <18 years SOF/VEL 400 mg/100 mg QD for 12 weeks. Key efficacy endpoint was SVR12. Safety was assessed by adverse events (AEs) and clinical/laboratory data. Intensive pharmacokinetic sampling on Day 7 in a subgroup of patients of each age group was done to confirm the appropriateness of the chosen dose.

Results 102 patients 12 to <18 years and 73 patients 6 to <12 years were enrolled. GT distribution was 75% GT1, 5% GT2, 13% GT3, 3% GT4, 3% GT6; 51% female, 80% white, 85% treatment naïve, and 91% vertically infected. Intensive pharmacokinetics confirmed that the doses selected were appropriate. SVR12 rate was 95% (97/102) and 92% (67/73) among patients 12 to <18 years and 6 to 12 years respectively; 1 patient in each age group had virologic failure, the remaining patients did not achieve SVR for non-virologic reasons. Most AEs were mild or moderate. 5 subjects had serious AE none of which was attributed to treatment, 2 patients discontinued treatment due to AEs and considered treatment unrelated. The most common AEs (≥15%) were headache, fatigue, and nausea in adolescents and vomiting, cough and headache in 6 to <12 years.

Conclusions In patients 6 to <18 years with GT1, 2, 3, 4 or 6 CHC infection, treatment with SOF/VEL for 12 weeks resulted in ≥ 92% SVR12 rate. SOF/VEL was well tolerated, supporting its potential as a treatment option for children 6 to 17 years of age. The study is ongoing in children aged 3 to <6 years old.

IDDF2020-ABS-0060 IMPACT OF PRIOR TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT DURATION ON TENOFOVIR ALAFENAMIDE (TAF) SAFETY PROFILE IN VIRALLY SUPPRESSED CHRONIC HBV PATIENTS SWITCHED FROM TDF TO TAF

1Henry Lik Yuen Chan*, 2Pietro Lampertico, 3Sang Hoon Ahn, 4Scott Fung, 5Ho Bae, 6Alinor Ramji, 7Jung Sung Lee, 8Stephen Alkhas, 9Stuart Gordon, 10Charles Phan, 11Susanna Tan, 12John Flaherty, 13Anuj Gaggar, 14George Wu, 15Vithika Suri, 16Danyel Lau, 17Kwan Soo Byun, 18Kosh Agarwal, 19Young-Suk Lim, 20Marta Buti, 21Institute of Digestive Disease, Department of Medicine and Therapeutics, and State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong; 22Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Italy; 23Yonsei University College of Medicine, Korea, South; 24Toronto Centre for Liver Disease, Toronto General Hospital; 25University Health Network, Canada; 26Asian Pacific Liver Center, St. Vincent Medical Center, USA; 27The University of British Columbia, Canada; 28Inje University College of Medicine, Korea, South; 29University of Alberta, Edmonton, Canada; 30Henry Ford Health System, USA; 31Greater Houston Gastroenterology, Sugar Land, USA; 32Gilead Sciences, Inc., USA; 33Beth Israel Deaconess Medical Center, Harvard Medical School, USA; 34Korea University Guro Hospital, Korea, South; 35Institute of Liver Studies, King’s College Hospital, UK; 36Asian Medical Center, University of Ulsan College of Medicine, Korea, South; 37Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Hospital Universitari Vall Hebron, Barcelona

10.1136/gutjnl-2020-IDDF.143

Background TAF demonstrated noninferior efficacy to TDF with a superior bone and renal safety profile, in viremic chronic HBV (CHB) patients through week 96, and in virally suppressed patients switched from TDF to TAF at 48 weeks. The duration of prior TDF therapy may influence the degree and rate of recovery of bone and renal function following switch to TAF. Here, we evaluate the impact of prior TDF treatment duration on the safety profile of TAF in virally suppressed patients.

Methods In a double-blind, randomized, multicenter, active-controlled, Phase 3 study, 488 CHB patients who were virologically suppressed on TDF for 1 year, and on TDF monotherapy for 6 months were randomized 1:1 to switch to TAF or continue TDF for 48 weeks. In patients originally randomized to receive TAF, renal, bone, and lipid parameters were categorically evaluated by the duration of prior TDF treatment:

Results Of the 243 patients switched to TAF from TDF, 105 (43%) and 138 (57%) had received TDF for 50 years, 74% male, 80% Asian, median eGFRCG 91 mL/min, 4% and 12% had osteoporosis at hip and spine, respectively. Similar changes in renal, bone, and lipid parameters following 48 weeks of TAF treatment were observed by treated duration of TAF.